Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

NCT07387471 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Waldenstrom Macroglobulinemia
Lymphoplasmacytic Lymphoma

Interventions

DRUG: Venetoclax

Sponsor

AbbVie